Why the study?
Does stimulation by various agonists alter phospholipase C activity in platelets from Bernard-Soulier syndrome patients compared to controls?
Does stimulation by various agonists alter phospholipase C activity in platelets from Bernard-Soulier syndrome patients compared to controls?
Bernard-Soulier syndrome platelets exhibit a postreceptor defect in phospholipase C activation, providing mechanistic insights into platelet activation pathways.
Hypothesis-generating for phospholipase C defects in Bernard-Soulier syndrome; clinical relevance remains uncertain pending human validation.
The levels of glycoprotein (GP) Ib and GPV and phospholipase C activity were measured in platelets from three Bernard-Soulier syndrome patients. The patients' platelets had 46%, 46%, and 24% of control levels of GPIb alpha and 43%, trace, and 13% of control levels of GPV as determined by immunoblot analysis. Stimulation by thrombin, trypsin, the thromboxane analogue U46619, and the combination of U46619 and trypsin caused the formation of [32P]phosphatidic acid, an index of phospholipase C activity, in [32P]orthophosphate-prelabeled platelets. With all agonists, however, the formation of [32P]phosphatidic acid was markedly reduced in Bernard-Soulier syndrome platelets compared with control platelets. These data indicated a postreceptor defect in phospholipase C activation in Bernard-Soulier syndrome platelets and confirmed earlier observations of potential proteolytic and nonproteolytic mechanisms of platelet activation.
No takes yet. Share an insight, caveat, or question.
McNicol et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: